Millions of individuals in the UK might be prescribed weight loss pills indefinitely, according to groundbreaking research suggesting their effectiveness in long-term weight management.
Research presented at the European Congress on Obesity in Istanbul revealed that oral appetite-suppressing medications could help sustain weight loss in individuals discontinuing injectable treatments. These pills, like orforglipron, could potentially serve as replacements for medications addressing conditions such as high blood pressure and Type 2 diabetes, and may even be administered preventatively to combat obesity.
Dr. Louis Aronne, the study’s lead author from the Weill Cornell Medicine center in New York, emphasized the concept of a lifelong daily pill regimen for obesity treatment, drawing parallels to managing conditions like hypertension and diabetes continuously. The broad impact of treating obesity extends to addressing multiple associated health issues.
Experts highlighted the potential of weight loss drugs to prevent over 200 diseases linked to obesity, with plans to expand access through the UK’s National Health Service (NHS). Currently, around 2.5 million individuals in the UK receive weight loss injections, predominantly through costly private prescriptions, but the NHS aims to introduce treatments like Wegovy and Mounjaro to an anticipated 3.4 million people over the next 12 years.
While existing injectable options can lead to substantial weight loss, they often prompt side effects such as nausea and digestive issues, leading some users to discontinue treatment post-weight loss. Transitioning to oral pills is expected to offer a more cost-effective and accessible alternative in the future.
Clinical trials involving 376 patients in the US who switched to orforglipron after using Mounjaro injections demonstrated a 75% weight loss maintenance rate after a year. These advancements in weight management strategies could potentially transform obesity treatment by addressing the issue earlier in individuals with lower body mass indexes.
The Medicines and Healthcare products Regulatory Agency (MHRA) is currently evaluating an application from Eli Lilly to authorize orforglipron for sale in the UK, marking a significant step in expanding treatment options for obesity. The new pill formulations mimic the effects of GLP-1 hormones, similar to injectable counterparts, but with potential cost and convenience advantages.
The shift toward oral weight loss medications signifies a significant evolution in obesity management, offering a more user-friendly and accessible approach for individuals seeking effective long-term solutions.